Literature DB >> 12027254

Fc gamma receptor genes as risk markers for localized aggressive periodontitis in African-Americans.

Yali Fu1, Jonathan M Korostoff, Daniel H Fine, Mark E Wilson.   

Abstract

BACKGROUND: Receptors for the Fc fragment of immunoglobulin G (Fc gammaRs) play a crucial role in host defense against bacterial infection by linking humoral and cell-mediated immune responses. Allelic variants of certain Fc gammaRs have been shown to differ relative to their biologic activity. Thus, genes encoding allotypes with diminished activity have been suggested as potential risk factors for infectious diseases. The goal of this study was to determine whether specific Fc gammaRIIa, Fc gammaRIIIa, and Fc gammaRIIIb alleles and/or genotypes could be used to predict susceptibility to localized aggressive periodontitis (LAgP) in an African-American population.
METHODS: Whole blood or saliva was obtained from 48 LAgP and 67 periodontally-healthy African-American subjects. DNA was prepared from each sample. Fc gammaRIIa and Fc gammaRIIIa genotyping was analyzed by polymerase chain reaction (PCR) amplification of DNA with allele-specific primers followed by allele-specific restriction digestion of the products. Fc gammaRIIIb genotyping was done by allele-specific PCR.
RESULTS: There was a statistically significant over-representation of the Fc gammaRIIIb-NA2 allele in LAgP patients compared to controls (P = 0.024). Relative to the Fc gammaRIIIb-NA1/NA2 and homozygous NA1/NA1 genotypes, the prevalence of the Fc gammaRIIIb NA2/NA2 genotype was higher in the LAgP group relative to the control population. Individuals expressing this genotype appeared at greater risk for developing LAgP (odds ratio 2.271, 95% confidence interval: 1.005 to 5.132). There were no significant differences in the distribution of the Fc gammaRIIa H/R or Fc gammaRIIIa-158 F/V genotypes nor their allelic frequencies between the LAgP patients and controls.
CONCLUSIONS: These data suggest that the Fc gammaRIIIb NA2 allele and/or NA2/NA2 genotype may represent risk markers for susceptibility to LAgP in African-Americans.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12027254     DOI: 10.1902/jop.2002.73.5.517

Source DB:  PubMed          Journal:  J Periodontol        ISSN: 0022-3492            Impact factor:   6.993


  6 in total

Review 1.  Genetic polymorphisms and periodontal disease in populations of African descent: A review.

Authors:  P F Gonçalves; T H Harris; T Elmariah; I Aukhil; M R Wallace; L M Shaddox
Journal:  J Periodontal Res       Date:  2017-11-05       Impact factor: 4.419

2.  Associations between FCGR2A rs1801274, FCGR3A rs396991, FCGR3B NA1/NA2 polymorphisms and periodontitis: a meta-analysis.

Authors:  Gwan Gyu Song; Young Ho Lee
Journal:  Mol Biol Rep       Date:  2013-05-07       Impact factor: 2.316

3.  Low copy number of the FCGR3B gene and rheumatoid arthritis: a case-control study and meta-analysis.

Authors:  Scott W Graf; Sue Lester; Johannes C Nossent; Catherine L Hill; Susanna M Proudman; Anita Lee; Maureen Rischmueller
Journal:  Arthritis Res Ther       Date:  2012-02-07       Impact factor: 5.156

4.  Epigenetic biomarkers: a step forward for understanding periodontitis.

Authors:  Anders M Lindroth; Yoon Jung Park
Journal:  J Periodontal Implant Sci       Date:  2013-06-30       Impact factor: 2.614

5.  Impaired neutrophil directional chemotactic accuracy in chronic periodontitis patients.

Authors:  Helen M Roberts; Martin R Ling; Robert Insall; Gabriela Kalna; Julia Spengler; Melissa M Grant; Iain L C Chapple
Journal:  J Clin Periodontol       Date:  2015-01-08       Impact factor: 8.728

6.  GWAS for Interleukin-1β levels in gingival crevicular fluid identifies IL37 variants in periodontal inflammation.

Authors:  Steven Offenbacher; Yizu Jiao; Steven J Kim; Julie Marchesan; Kevin L Moss; Li Jing; Kimon Divaris; Sompop Bencharit; Cary S Agler; Thiago Morelli; Shaoping Zhang; Lu Sun; William T Seaman; Dale Cowley; Silvana P Barros; James D Beck; Matthias Munz; Arne S Schaefer; Kari E North
Journal:  Nat Commun       Date:  2018-09-11       Impact factor: 14.919

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.